Patient Guide: Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 27 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT04643002
Status: 🟢 Enrolling Now
Condition: Plasma Cell Myeloma Refractory
Phase: PHASE1, PHASE2

Where You Can Participate

This study is available at 27 locations across the country.

Top locations include:
  • • Atlanta, Georgia
  • • Chicago, Illinois
  • • Ann Arbor, Michigan
  • • And 24 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol - Join Clinical Trial NCTNCT04643002

How to Join This Clinical Trial - NCTNCT04643002

Learn how to participate in this PHASE1, PHASE2 trial studying an investigational therapy for Plasma Cell Myeloma Refractory. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Plasma Cell Myeloma Refractory. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Plasma Cell Myeloma Refractory
Treatment Being Tested
Investigational treatment
Study Phase
PHASE1, PHASE2 - Safety and effectiveness study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT04643002 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 27 locations. Find a study site near you:

Clinical Research Site

Atlanta, Georgia 30322-0001 - United States

Status: RECRUITING

Clinical Research Site

Chicago, Illinois 60612 - United States

Status: COMPLETED

Clinical Research Site

Ann Arbor, Michigan 48109 - United States

Status: RECRUITING

Clinical Research Site

Buffalo, New York 14263 - United States

Status: RECRUITING

Clinical Research Site

Wollongong, New South Wales 2500 - Australia

Status: RECRUITING

Clinical Research Site

Melbourne, Victoria 3065 - Australia

Status: RECRUITING

Clinical Research Site

Richmond, Victoria 3121 - Australia

Status: RECRUITING

Clinical Research Site

Lille, 59037 - France

Status: RECRUITING

Clinical Research Site

Nantes, 44093 - France

Status: RECRUITING

Clinical Research Site

Paris, 75015 - France

Status: RECRUITING

And 17 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE1, PHASE2 clinical trial for Plasma Cell Myeloma Refractory:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships